A Phase IV multicentre, open-label, non-interventional study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with Afinitor (everolimus [RAD001]) in combination with exemestane, after progression of therapy with nonsteroidal aromatase inhibitors.

Trial Profile

A Phase IV multicentre, open-label, non-interventional study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with Afinitor (everolimus [RAD001]) in combination with exemestane, after progression of therapy with nonsteroidal aromatase inhibitors.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Everolimus (Primary) ; Exemestane
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 12 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 19 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top